Therapeutic effect of the gastrin receptor antagonist, CR2093 on gastrointestinal tumour cell growth. by Watson, S. A. et al.
Br. J. Cancer (1992), 65, 879-883
© Macmillan Press Ltd.,
Therapeutic effect of the gastrin receptor antagonist, CR2093 on
gastrointestinal tumour cell growth
S.A. Watson', D.M. Crosbee', D.L. Morris3, J.F.R. Robertson2, F. Makovec4, L.C. Rovati4 &
J.D. Hardcastle2
'Cancer Research Campaign Laboratories, University ofNottingham, Nottingham NG7 2RD, UK; 2Department ofSurgery,
University Hospital, Nottingham NG7 2UH, UK; 3Department ofSurgery, University ofNew South Wales, Australia; 4Rotta
Research Laboratorium, 20052 Monza, Milan, Italy.
Summary The gastrin receptor antagonist, CR2093, competed with I'25-gastrin-17 (5 x 10 '° M) for binding
to gastrin receptors on the rat pancreatic adenocarcinoma, AR42J (CR2093 concentration inducing 50% of
I1-gastrin-17 binding (IC50) was 8 x I0-S M), on the human gastric adenocarcinoma, MKN45 (IC50 5.5 x
10- M) and the human colo-rectal adenocarcinoma C523 (IC50 > 0-4 M). Intravenous administration of
CR2093 (40 mg kg-' day-') reduced the gastrin-17 stimulated growth of AR42J xenografts in nude mice to
below that of the original basal growth (P = 0.0166 from basal and P = 0.0109 from gastrin stimulated
growth). CR2093 administration also reduced the gastrin-stimulated growth of MKN45 xenografts (P = 0.045)
but failed to inhibit the gastrin enhanced proliferation of C523 xenografts. This may be related to the affinity
(Kd) of the gastrin receptors present on the xenograft lines as the Kds of the two xenografts inhibited by
CR2093 were 4.6 x 10- 10 M (AR42J) and 1.2 x 10-9 M (MKN45) respectively whereas the Kd of C523 was of
higher affinity (2.2 x 10-10 M). GR antagonists may be a viable therapeutic option for gastrin receptor positive,
gastro-intestinal tumours.
The extent to which gastro-intestinal (G.I.) tumours are hor-
monally controlled is unknown. However, a number of GI-
associated peptide hormones, including gastrin, have been
shown to increase the growth of gut tumours (Review, Town-
send et al., 1987). In addition, gastrin receptors (G.R.) have
been found on pancreatic (Scemama et al., 1987), gastric
(Weinstock & Baldwin, 1988) and colo-rectal (Upp et al.,
1989) tumours. It is possible that agents which bind to GR
may have a therapeutic role, preventing growth stimulation
by the ligand, in the same way that tamoxifen, an oestrogen
receptor antagonist, prevents growth stimulation of breast
cancer by oestradiol (Furr & Jordan, 1984).
In this study, the effect of the GR antagonist, CR2093 was
examined on the basal and gastrin-stimulated growth of the
following GR-positive xenografts; AR42J (rat pancreatic),
MKN45 (human gastric) and C523 (human colo-rectal).
Materials and methods
Tumour cell line
AR42J, a rat pancreatic tumour cell line (Jessop & Hay,
1980), MKN45, a human gastric tumour line (Motoyama &
Watanabe, 1985) and C523 a human colo-rectal tumour line
(derived in the Cancer Research Campaign Laboratories,
Nottingham), were maintained in vitro in RPMI culture
medium (Flow Labs., Irvine, Scotland) containing 10% heat-
inactivated foetal calf serum (FCS, Gibco, Paisley, Scotland).
Xenografts were initiated at a subcutaneous (s.c.) site on
the left hand flank of immuno-compromised male nude mice
(Harlan-Olac, Bicester, UK) by injection of cells (5 x 106 to
107 cells per site). After approximately 14 days, tumour
growth was evident, which reached maximal size after 3 to 4
weeks.
GR antagonist, CR2093
The GR antagonist CR2093 (a non-peptidic glutamic acid
derivative; R-4-(3-chlorobenzamido)-5-(3,3-dimethyl butyl-
amino)-5-oxo-pentanoic acid; M.W. 368.87) was provided by
Rotta Research Laboratories, Milan, Italy. CR2093 has been
shown to bind to guinea pig gastric glands and to mouse
cerebral cortex membranes at a concentration range of
10-7 M to 10-' M. In addition, in vivo, CR2093 antagonised
in a dose-dependent fashion, gastric acid secretion in perfused,
anaesthetised rat stomach, induced by pentagastrin. The
CR2093 dose that reduced gastric stimulated secretion by
50% and shown to be non-toxic, was 40 mg kg-' which was
the dose chosen for the in vivo experiments performed in the
present study (L.C. Rovati: Communication to the Society
for Drug Research, London, March 1991). The antagonist
was dissolved in sterile distilled water containing stoichiomet-
ric quantities of sodium hydroxide and stored at -20°C at
1 mg ml for the in vitro study from which it was infused
into culture medium at the required concentration. For in
vivo studies, CR2093 was dissolved in 0.9% saline, with
stoichiometric quantities of sodium hydroxide.
Gastrin receptor binding studies
Cells were harvested from semi-confluent cell monolayers
with 0.025% EDTA (Sigma, Poole, Dorset, UK) for AR42J
and C523 cells and 0.025% trypsin (Sigma), 0.5% EDTA for
MKN45 cells. The cells were then washed in minimal Eagles
medium (MEM, Flow Labs) containing 0.5% Bovine Serum
Albumin (BSA, Sigma) and 10 jig ml-' aprotinin (Sigma),
and aliquoted into tubes at 2 x 105 cells per tube. '25I-gastrin-
17 ('25I-G17, NEN-Dupont, Stevenage, Herts, UK (Specific
activity 2200 Cimmol-1)) at a final concentration between
5 x 10-"° and 10-9 M was premixed with either CR2093 (10-3
to 10-7 M) or gastrin-17 (G17, Sigma, 10-5 M) and added to
the cells (three replicates were performed per concentration).
The cells were vortexed and incubated for 1 h at 22°C, before
being washed in ice cold MEM by centrifugation and associ-
ated radio-activity counted on a y-counter. Results were cal-
culated as the % inhibition of specific '251I-G17 binding
(specific binding was measured when cells were incubated
with '25I-G17, in the presence of 10-5 M G17).
Scatchard analyses (Scatchard, 1948) were performed on
all three cell lines. '25I-G17 at concentrations between 5 x
10-" and 10-9 M was incubated with/without 10-5 M
unlabelled G17 as described above. Specific binding was
calculated at each '251-G17 concentration and the receptor
affinity (Kd) and maximal receptor capacity (Bmax) cal-
culated from a ligand pc curve-fitting programme (Munson &
Rodbard, 1980).
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Xenograft studies
For transplantation of xenografts for experimental purposes,
established xenograft tissue was surgically excised, finely
minced and 3 to 5 mm3 tissue pieces grafted aseptically s.c.
into 40 nude mice. The animals were then randomised into
four experimental groups of ten mice.
The effect of CR2093 administration was examined on
basal and gastrin-stimulated growth. Human G17 was
administered via osmotic mini-pumps (Model 2002, Alzet,
Charles River, Kent, UK) at a concentration of 10tig
mouse- day-' which pumped G17 from day 0 to day 17.
Control mice received sterile distilled water (which was also
delivered by osmotic mini-pumps).
CR2093 was administered at a dose of 40 mgkg-' day-',
intravenously (i.v.), every morning from day 0 and therapy
was terminated at day 20. Control mice received 0.9% saline.
Tumour growth was monitored three times weekly by an
experienced, independent observer by measurement of the
largest perpendicular diameters of the tumour, from which
the cross-sectional areas were derived.
The four animal groups were as follows:
Group I Water containing pumps, saline i.v.
Group II G17 containing pumps, saline i.v.
Group III Water containing pumps, CR2093, i.v.
Group IV G17 containing pumps, CR2093, i.v.
In vivo biodistribution ofCR2093
The serum levels of CR2093 following i.v. administration
were followed for 24 h. CR2093 (40 mgkg-') was injected
into 12 nude mice and three animals were killed after 1, 3, 7
and 24 h and blood collected by cardiac puncture. After
allowing for clot formation, serum was removed for analysis.
In parallel, animals injected i.v. with saline (control treat-
ment) were also killed and bled at the same time points.
For analysis of CR2093 levels in the serum, a GR binding
assay was performed with AR42J cells. The neat sera were
admixed with 5 x 10-0M '25I-G17 and incubated with
AR42J cells in suspension (as described in the GR binding
studies section). Inhibition of binding of '25I-G17 to AR42J
by the sera was measured and related to a standard curve in
which known concentrations ofCR2093 were diluted in pool-
ed nude mouse serum and competed with 5 x 10-10M 125I-
G17 for binding to AR42J cells. The standard curve was used
to relate the inhibition achieved with unknown sera to a
CR2093 concentration. The levels of inhibition of binding of
125I-G17 were measured in the sera from the saline controls
and 100% inhibition of '25I-G17 binding was measured by
displacement with a saturating dose of G17 (10-5 M) diluted
in mouse sera.
UKCCCR Guidelines were adhered to in all animal experi-
mentation.
Statistics
For the GR studies, statistical significance was determined by
the Student's t-test. For the in vivo studies, due to the non-
parametric distribution of the data, the Mann Whitney U
Wilcoxon Rank Sum W statistical test was performed, as
analysed with the SPSS/PC + statistical package for the IBM
PC.
Results
Gastric receptor binding studies
The Kd and Bmax of GR on the three cell lines were
calculated by Scatchard analysis (Figure 1). The Kd and
Bmax for AR42J were 4.6 x 10-10 M and 5.5 fmols per I05
cells, for MKN45, 1.2 x 10-9 M and 12.8 fmols per 105 cells
and for C523, 2.2 x 10-10 M and 0.37 fmols per 105 cells,
respectively.
The ability of CR2093 to displace '25I-G17 from GR was
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Figure 1 Scatchard plots of specific '25I-G17 binding to: a,
AR42J; b, MKN45; c, C523. Results are expressed as specifically
bound '251-G17 (expressed as fmols 105 cells-') vs Bound '2511
G17/Free 251I-G17.
examined on the three cell lines. The % inhibition of specific
'251-GI7 binding was evaluated at each CR2093 concentra-
tion, with the level of inhibition achieved with excess
unlabelled G17 (10-5 M, 5 x 105 times excess) taken as 100 (it
was assumed that any '251-Gl7 not displaced by a saturating
concentration of 10-5 M G17 was non-specifically bound and
was always between 5 and 10% of the total bound). The
mean and the standard deviation of inter-experimental varia-
tion from four experiments for AR42J and two experiments
for C523 and MKN45 are shown (Figure 2).
The concentration of CR2093 inducing 50% inhibition of
5 x 10-10 M '25I-G17 binding (ICm) was 8 x 10-5 for AR42J
cells, 5.5 x 10-5 M for MKN45 and > 10-4 M for C523. This
compares to 6 x 10-9 M when G17 is the competing ligand
(Watson et al., 1991).
In vivo biodistribution ofCR2093
From the standard curve established by competing known
concentrations of CR2093 diluted in nude mouse serum with
5 x 10-' M 1251-G17 for binding to GR on AR42J, CR2093
levels in the serum following i.v. injection of 40mgkg-'
CR2093 were followed.
One hour after the i.v. injection of CR2093 the serum level
was 7.0 x 10-5 M which had dropped to 4.0 x 10-5 M after
3 h, 5.4 x 10-7M after 7 h and <2.7 x 10-7M after 24 h
(Table I). Serum from mice treated with saline did not com-
plete with '25I-G17 for binding to GR on AR42J.
The effect ofCR2093 on the basal and GI7-stimulatedgrowth
ofAR42Jxenografts
Figure 3 (a and b) shows the mean cross-sectional areas of
AR42J xenografts in the four groups of experimental ani-
mals. At the termination of the experiment (day 24), Group
II had significantly greater cross-sectional tumour areas when
compared to Group I (P = 0.0158, Figure 3a). In compari-
son, Group IV had significantly lowered cross-sectional
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Figure 2 Percentage inhibition of specific "1I-G17 binding to
GR on *-* AR42J, 0-0 MKN45 and A-A C523 by
increasing concentrations of CR2093. The data shown is the
mean of four individual experiments for AR42J and two for
MKN45 and C523, with the error bars indicating the standard
deviation of the mean (s.d.) between experiments.
Table I Serum levels ofCR2093 in nudemiceatincreasing timepoints
following i.v. administration of40 mg kg-'
Time after administration CR2093 levels s.d. CR2093
(hours) (jLgml-') (dIgml-') (M)
1 26.0 1.50 7.0 x 10-5
3 15.0 0.50 4.0 x 10-5
7 0.2 0.04 5.4 x 10-7
24 <0.1 0.01 <2.7X 10-7
s.d., standard deviation of mean of three replicates.
3
tumour areas when compared to both Group I (P = 0.0166)
and Group II (P = 0.0109). However, the cross sectional
tumour areas of Group III were not significantly different
from that of Group I (Figure 3b).
The final mean tumour weights obtained at day 24 are
shown in Figure 4a. The tumour weights of Group II were
significantly elevated when compared to Group I (P = 0.033).
The tumour weights of Group IV were significantly lowered
from Group II (P = 0.0355) and Group I (P = 0.0403). How-
ever, the tumour weights of Group III were not significantly
different from those of Group I.
The final mean body weights of the experimental animals
(minus the tumours) were the same in all experimental
groups (Figure 4b).
The effect ofCR2093 on the basal and GI7 stimulatedgrowth
ofthe human GI lines; C523 and MKN45
Figure 5 (a and b) shows the mean cross-sectional areas of
C523 xenografts. At the termination (day 25) Group II had a
significantly greater cross-sectional area than Group I (P =
0.0101). Group III was not significantly different from Group
I and Group IV was not significantly reduced from Group II
or Group I.
Figure 6 (a and b) shows the mean cross-sectional areas of
MKN45 xenografts. At experiment termination (day 14),
Group II was significantly greater than Group I (P = 0.0216).
Group III was not significantly different from Group I.
However, Group IV was significantly reduced from Group II
(P = 0.0454) but not Group I.
Discussion
GI tumours are known to express GR. AR42J (rat pancrea-
tic), MKN45 (human gastric), and C523 (human colo-rectal)
tumour cell lines express functional, high affinity GR which
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Figure 3 Effect of CR2093 on the basal and gastrin-stimulated
growth of AR42J xenografts. a, 0-0 Group I, pumped H2O,
saline i.v., 0-0 Group II pumped G17 (101ag mouse day),
saline i.v. b, *-* Group III, pumped H2O, CR2093 (40 mg
kgday) i.v.; 0 0 Group IV, pumped G17, CR2093, i.v. The
data shown is the mean cross-sectional area from single experi-
ment with ten animals per group with the error bars indicating
the standard error of the mean (s.e.). Day 20; *P= 0.0296 from
Group I, **P<0.001 from Group I and ns from Group II. Day
22; *P = 0.0251 from Group I, **P>0.001 from Group I and ns
from Group II. Day 24; *P = 0.0158 from Group I, **P= 0.0166
from Group I and P = 0.0109 from Group II. All statistical
analyses were determined by the Mann Whitney U test.
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Figure 4 Effect of CR2093 on the basal and gastrin-stimulated
growth of AR42J xenografts. a, Final mean tumour weights at
the termination of the experiment (day 24). *P= 0.033 when
compared to Group I, **P = 0.0355 from Group II and P=
0.0403 from Group I. All statistical analyses were determined by
the Mann Whitney U test. (n = 10 animals/group). The s.e. of the
mean is shown by the error bars. b, Final mean animal weights at
day 24 (body weight minus tumour weight). (n = ten animals per
group). The s.e. of the mean is shown.
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Figure 5 Effect of CR2093 on the basal and gastrin-stimulated
growth of C523 xenografts. a, *-* Group I, pumped H20,
saline i.v.; 0-0 Group II, pumped G17 (10 ltg mouse/day),
saline i.v. b, *-* Group III, pumped H20, CR2093 (40mg
kg day) i.v., 0-0 Group IV, pumped G17, CR2093 i.v.
*P = 0.0101 from Group I, as determined by Mann Whitney U
(n = 10 animals per group). The error bars indicate the s.e. of the
mean.
0.04
4
a
6 8 10 12 14 16
Time (days)
b
6 8 10 12
Time (days)
14 16
Figure 6 Effect of CR2093 on the basal and gastrin-stimulated
growth of MKN45 xenografts. a, 0-0 Group I, pumped H20,
saline i.v.; 0-0 Group II, pumped G17 (10lg mouse/day),
saline i.v. b, *-0 Group III, pumped H20, CR2093 (40mg
kgday) i.v., 0-0 Group IV, pumped G17, CR2093 i.v. *P=
0.0216 from Group I, **P=0.0454 from Group II (n = 10
animals per group). The error bars indicate the s.e. of the mean.
initiate a mitogenic response to G17 as shown in the present
study.
For GR antagonists to compete with gastrin-stimulated
growth in vivo they must be either potent (with respect to
receptor binding) or be able to achieve high enough serum
concentrations to effectively compete with circulating G17 for
GR binding. With respect to CR2093, the latter scenario
existed as due to its favourable pharmokinetics, CR2093 was
administered i.v. at a dose of 40 mgkg-' daily (which lacked
toxicity as shown by the final animal weights). The CR2093
concentrations achieved in the serum for at least the first 3 h
were between 7 and 4 x 10- M which were competing with
fasting serum G17 levels of 1.55 x 10-` M which are known
to be attained when delivering G17 by osmotic mini pump at
10 lOg mouseday (Watson et al., 1989).
CR2093 competed with 5 x 10-1 M 1251I-G17 for binding to
GR on all three cell lines. With AR42J the ICowith CR2093
was 8 x I0-5M, which was 1.3 x 104 times higher than the
ICR, with the natural ligand, G17, when competing with the
same concentration of '25I-G17 (Watson et al., 1991b).
CR2093 displaced 251I-G17 from MKN45 cells with an ICo
of 5.5 x 10-5 M and C523 with and IC5ogreater than 10-4 M.
The trend in IC5os indicated that the higher the affinity of
the GR the greater the CR2093 concentration required to
compete with G17 for binding to the GR. This was reflected
in the in vivo studies in that the serum levels of CR2093
attained competed with G17 and inhibited G17-stimulated
growth of MKN45 and AR42J of Kds 1.2 x 10-9M and
6.6 x 10`0 respectively but failed to inhibit the G17 stimu-
lated growth of C523 which has GR of Kd 2.2 x 1010 M.
Future studies will be aimed at increasing the in vivo dosage
administered to animals bearing C523 xenografts to try and
achieve competitive serum levels of CR2093.
By 7 h, the serum level of CR2093 had dropped to 5.4 x
I0- M which may not have competed with serum G17 levels
(achieved by the osmotic mini-pump) for GR binding (50%
inhibition of 5 x 10-`oM G17 binding was achieved at
CR2093 concentrations > 5 x 10-5 M for all three cell lines,
Figure 2). This indicates the inhibition of G17-stimulated
AR42J and MKN45 xenograft growth may have been
achieved by serum CR2093 levels which were high enough to
compete with G17 for GR binding for up to 7 h each day.
Relating this to the clinical situation, it may be that long
term maintenance of serum CR2093 concentrations may not
be essential for a therapeutic effect, providing the peak serum
concentration attained is sufficiently high.
The level of inhibition of G17-stimulated AR42J growth
achieved with CR2093 was similar to that achieved with the
more potent benzodiazepine GR antagonist, L-365,260 (Bock
et al., 1989) examined in the same xenograft system (IC50 of
L-365,260, was 4.5 x 10- M when competing with 5 x 10-10
M '25I-G17) and administered at a dose of 5 mg kg- day-
(Watson et al., 1991b). L-365,260, although being 1.8 x 103
times more potent with respect to GR binding than CR2093,
was insoluble, and for in vivo studies was dosed orally in the
form of a suspension in methyl cellulose. It is likely that
unfavourable pharmokinetics prevented L-365,260, from hav-
ing a more potent effect on G17-stimulated growth of AR42J
xenografts.
With AR42J xenografts (but not MKN45 xenografts),
when CR2093 and G17 were co-administered, tumour
growth was reduced below that of the untreated control.
Similar findings have been reported by Singh et al. (1986) for
the mouse colon tumour cell line, MC26 following treatment
with a combination of pentagastrin and proglumide. Singh
and colleagues showed that proglumide inhibited the up-
regulatory effect of pentagastrin on type I GR. In the present
study, the effects of G17 and CR2093 on the number and
affinity of GR, alone and in combination were not investi-
gated for the three cell lines. Future studies aimed at measur-
ing such parameters may shed some light on the possible
mechanism responsible for the inhibitory effects of the
CR2093/G17 combination on AR42J xenografts.
It has been shown that patients with colo-rectal and gastric
tumours may have elevated serum gastrin levels (Smith et al.,
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1987; McGuigan & Trudeau, 1973). In addition, human GI
tumour cells are capable of producing gastrin in an auto-
crine/paracrine manner (Watson et al., 1991a; Hoosein et al.,
1990; Baldwin et al., 1990). Thus GR antagonists, in patients
with GI tumours may have to compete with high levels of
serum gastrin and unknown concentrations of tumour-assoc-
iated gastrin. In the present study, it has been shown that
gastrin receptor antagonists can block the growth-promoting
effects of elevated serum gastrin levels in 2/3 GI tumour
xenograft models. In addition the gastrin and cholecystokinin
(CCK) receptor antagonists, proglumide (Hoosein et al.,
1988) and CR1409 (lorglumide) (Watson et al., 1989) respec-
tively inhibited the basal growth ofGI tumours cells in which
GI peptide hormones may be acting in an autocrine/para-
crine manner.
In conclusion, potent GR antagonists (with respect to
receptor binding) with favourable pharmokinetics may be
therapeutically effective in patients with GR positive GI
tumours.
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